AAAAAA
Results:
1-8
|
Results: 8
Authors:
Baas, H
Zehrden, F
Selzer, R
Kohnen, R
Loetsch, J
Harder, S
Citation: H. Baas et al., Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease, CLIN PHARMA, 40(5), 2001, pp. 383-393
Authors:
Dietz, M
Harder, S
Graff, J
Kunig, G
Vontobel, P
Leenders, KL
Baas, H
Citation: M. Dietz et al., Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[F-18]levodopa positron emission tomography in patients with Parkinson's disease, CLIN PHARM, 70(1), 2001, pp. 33-41
Authors:
Reuter, I
Harder, S
Engelhardt, M
Baas, H
Citation: I. Reuter et al., The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa, MOVEMENT D, 15(5), 2000, pp. 862-868
Authors:
Baas, H
Citation: H. Baas, Dyskinesia in Parkinson's disease. Pathophysiology and clinical risk factors, J NEUROL, 247, 2000, pp. 12-16
Authors:
Jost, WH
Berg-Mantkowski, A
Baas, H
Gemende, I
Glass, J
Kogan, E
Schneider, E
Storch, A
Citation: Wh. Jost et al., Workshop III: Late motor complications of Parkinson's disease, J NEUROL, 247, 2000, pp. 38-39
Authors:
Reuter, I
Engelhardt, M
Freiwaldt, J
Baas, H
Citation: I. Reuter et al., Exercise test in Parkinson's disease, CLIN AUTON, 9(3), 1999, pp. 129-134
Authors:
Reuter, I
Engelhardt, M
Stecker, K
Baas, H
Citation: I. Reuter et al., Therapeutic value of exercise training in Parkinson's disease, MED SCI SPT, 31(11), 1999, pp. 1544-1549
Authors:
Baas, H
Citation: H. Baas, Therapy strategies in de novo Parkinson patients, NERVENARZT, 70, 1999, pp. S11-S18
Risultati:
1-8
|